ipamorelin 2mg reconstitution for Sale from Peptide Pros tesamorelin ipamorelin 12 2mg dosage

2 way Dual Activation GHRH-R (CJC-1295) + GHS-R1a (Ipamorelin) two complementary pituitary targets 2-4x GH AUC Demonstrated Synergy Area under the GH curve 2 to 4 times greater than each peptide in monotherapy 5.8 - 8.1 days CJC-1295 Half-Life Sustained elevation of IGF-1 for 9 to 11 days after a single injection 10 mg Pre-formulated mix 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial | Purity 99% HPLC Selective Hormonal Profile Ipamorelin: no increase in cortisol, prolactin or ACTH (Raun et al., 1998) Mechanism of Action Dual-Channel Synergy Simultaneous activation of GHRH-R and GHS-R1a for amplified GH stimulation GHRH Lane CJC-1295 GHRH Analog (Mod GRF 1-29) A synthetic peptide of 29 amino acids that selectively binds to the GHRH receptor on pituitary somatotroph cells

Lpez-Otn et al., 2013

CJC-1295 IPA NO DAC (5mg/5mg) Growth hormone-releasing hormone analog without DAC modification for shorter half-life and rapid onset

Repeat: patients typically run 2 full cycles per year on this protocol

How Is Timing Modeled In Community Research Protocols

Animal studies demonstrate that IGF-1 LR3 administration increases organ weight through enhanced cellular proliferation